Search

Icatibant

[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … results obtained from 3 double-blind, randomized, controlled clinical trials known as FAST 1, 2, and 3, where a median time to almost complete symptom relief was observed to be 8 hours compared to 36 hours for

Belantamab mafodotin

[L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide … [A216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the

Ancrod

and oxygen to portions of the brain, for which phase III trials are currently being conducted. … FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood

Sulthiame

Methyldopa

[A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. … [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects.

Human thrombin

Human thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting.

Chlorthalidone

Chlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment. … the risk of stroke, myocardial infarction, heart failure, and cardiovascular all-cause mortality in patients with hypertension.

Estradiol valerate

Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. … due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation

Fomivirsen

Fomivirsen is marketed under the trade name Vitravene for intravitreal injection and was the first antisense drug to be approved by the Food and Drug Administration (FDA). … The drug was withdrawn by the FDA because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development

Rusfertide

[L64113] It is the first hepcidin mimetic approved for polycythemia vera.[L64113] … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.